☐ |
Preliminary Proxy Statement |
☒ |
No fee required |
|
Ernest A. Bates, M.D.
David A. Larson, M.D., PhD S. Mert Ozyurek |
| | Daniel G. Kelly, Jr. Sandra A.J. Lawrence Raymond C. Stachowiak |
|
Name
|
| |
Fees Earned
or Paid in Cash(1) |
| |
Stock
Awards(2)(3) |
| |
Option
Awards(4)(5) |
| |
Total
|
| ||||||||||||
Daniel G. Kelly, Jr.
|
| | | $ | 20,000 | | | | | $ | 1,340 | | | | | $ | 2,907 | | | | | $ | 24,247 | | |
David A. Larson, M.D., PhD
|
| | | $ | 20,000 | | | | | $ | 1,340 | | | | | $ | 2,907 | | | | | $ | 24,247 | | |
Sandra A.J. Lawrence
|
| | | $ | 20,000 | | | | | $ | 1,340 | | | | | $ | 2,907 | | | | | $ | 24,247 | | |
S. Mert Ozyurek
|
| | | $ | 20,000 | | | | | $ | 1,340 | | | | | $ | 2,907 | | | | | $ | 24,247 | | |
John F. Ruffle
|
| | | $ | 20,000 | | | | | $ | 1,340 | | | | | $ | 2,907 | | | | | $ | 24,247 | | |
Raymond C. Stachowiak
|
| | | $ | 20,000 | | | | | $ | 1,340 | | | | | $ | 2,907 | | | | | $ | 24,247 | | |
Stanley S. Trotman, Jr.
|
| | | $ | 20,000 | | | | | $ | 1,340 | | | | | $ | 2,907 | | | | | $ | 24,247 | | |
| | |
Common Shares
Owned Beneficially |
| |||||||||
Name and Address of Beneficial Owner
|
| |
Amount and
Nature of Beneficial Ownership(2) |
| |
Percent of
Class(3) |
| ||||||
Directors and Named Executive Officers(1) | | | | | | | | | | | | | |
Ernest A. Bates, M.D.(4)
Chairman of the Board and Chief Executive Officer |
| | | | 712,205 | | | | | | 12.2% | | |
Daniel G. Kelly, Jr.(5)
|
| | | | 28,676 | | | | | | 0.5% | | |
David A. Larson, M.D., PhD(6)
|
| | | | 84,346 | | | | | | 1.5% | | |
Sandra A.J. Lawrence(7)
|
| | | | 15,385 | | | | | | 0.3% | | |
S. Mert Ozyurek(8)
|
| | | | 79,130 | | | | | | 1.4% | | |
John F. Ruffle(9)
|
| | | | 569,246 | | | | | | 9.9% | | |
Raymond C. Stachowiak(10)
|
| | | | 738,094 | | | | | | 12.7% | | |
Stanley S. Trotman, Jr.(11)
|
| | | | 264,803 | | | | | | 4.6% | | |
Ernest R. Bates(12)
Vice President of Sales and Business Development |
| | | | 105,743 | | | | | | 1.8% | | |
Craig K. Tagawa(13)
Senior Vice President, Chief Operating and Financial Officer |
| | | | 133,532 | | | | | | 2.3% | | |
All Current Directors & Executive Officers as a Group (10 people)(14)
|
| | | | 2,731,160 | | | | | | 42.8% | | |
5% or More Shareholders | | | | | | | | | | | | | |
None
|
| | | | | | | | | | | | |
Name and Principal Position
|
| |
Year
|
| |
Salary(1)
|
| |
Bonus
|
| |
Stock
Awards(2) |
| |
Option
Awards |
| |
All Other
Compensation(3) |
| |
Total
|
| |||||||||||||||||||||
Ernest A. Bates, M.D.,
Chairman of the Board and Chief Executive Officer |
| | | | 2018 | | | | | $ | 434,304 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 17,592 | | | | | $ | 451,896 | | |
| | | 2017 | | | | | $ | 434,304 | | | | | | — | | | | | $ | 44,337 | | | | | | — | | | | | $ | 20,890 | | | | | $ | 499,531 | | | ||
Craig K. Tagawa,
Chief Operating Officer and Chief Financial Officer |
| | | | 2018 | | | | | $ | 325,000 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 15,100 | | | | | $ | 340,100 | | |
| | | 2017 | | | | | $ | 325,000 | | | | | | — | | | | | $ | 39,413 | | | | | | — | | | | | $ | 15,600 | | | | | $ | 380,013 | | | ||
Ernest R. Bates,
Vice President of Sales and Business Development |
| | | | 2018 | | | | | $ | 250,000 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 18,918 | | | | | $ | 268,918 | | |
| | | 2017 | | | | | $ | 250,000 | | | | | | — | | | | | $ | 24,633 | | | | | | — | | | | | $ | 18,874 | | | | | $ | 293,507 | | |
| | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||||||||||||||
Name
|
| |
Number of
Securities Underlying Unexercised Options Exercisable (#) |
| |
Number of
Securities Underlying Unexercised Options Unexercisable (#)( 1) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Equity
Incentive Plan Awards: Number of Unearned Shares That Have Not Vested (#)(2) |
| |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares That Have Not Vested ($)(2) |
| ||||||||||||||||||
Ernest A. Bates, M.D.
|
| | | | 120,000 | | | | | | 30,000 | | | | | $ | 3.100 | | | | | | 12/29/19 | | | | | | 52,942 | | | | | $ | 126,002 | | |
Craig K. Tagawa
|
| | | | 120,000 | | | | | | 30,000 | | | | | $ | 2.820 | | | | | | 12/29/21 | | | | | | 47,059 | | | | | $ | 112,000 | | |
Ernest R. Bates
|
| | | | 90,000 | | | | | | 22,500 | | | | | $ | 2.820 | | | | | | 12/29/21 | | | | | | 29,412 | | | | | $ | 70,001 | | |
| | |
Performance-Based
Restricted Stock (#) |
| |
Performance-Based
Restricted Stock Value as of December 31, 2018 |
| ||||||
Dr. Ernest A. Bates,
Chairman and Chief Executive Officer |
| | | | 52,942 | | | | | $ | 126,002 | | |
Craig K. Tagawa,
Chief Financial Officer and Chief Operating Officer |
| | | | 47,059 | | | | | $ | 112,000 | | |
Ernest R. Bates,
Vice President of Sales and Business Development |
| | | | 29,412 | | | | | $ | 70,001 | | |
Plan Category
|
| |
Number of shares to
be issued upon exercise of outstanding options, warrants and rights |
| |
Weighted average
exercise price of outstanding options, warrants and rights |
| |
Number of shares
remaining available for future issuance |
| |||||||||
Equity compensation plans approved by security holders(1)
|
| | | | 845,396(2) | | | | | $ | 2.85(3) | | | | | | 316,412(4) | | |
Equity compensation plans not approved by security holders
|
| | | | N/A | | | | | | N/A | | | | | | N/A | | |
Total
|
| | | | 845,396 | | | | | | | | | | | | 316,412 | | |
|
Name and Position
|
| |
Number of
Units (#) |
| |
Dollar Value
of Units underlying Restricted Stock Units ($)(1) |
| ||||||
All continuing non-employee directors as a group (5 persons)
|
| | | | 12,500 | | | | | | 6,775 | | |
| | |
Audit
Fees(1) |
| |
Audit-
Related Fees(2) |
| |
Tax Fees(3)
|
| |
All
Other Fees(4) |
| |
Total Fees
|
| |||||||||||||||
2018
|
| | | $ | 239,000 | | | | | $ | 0 | | | | | $ | 130,000 | | | | | $ | 0 | | | | | $ | 369,000 | | |
2017
|
| | | $ | 274,000 | | | | | $ | 0 | | | | | $ | 106,000 | | | | | $ | 0 | | | | | $ | 380,000 | | |